Loss-of-function mutations in glutaminase (GLS), the enzyme converting glutamine into glutamate, and the counteracting enzyme glutamine synthetase (GS) cause disturbed glutamate homeostasis and severe neonatal encephalopathy. We report a de novo Ser482Cys gain-of-function variant in GLS encoding GLS associated with profound developmental delay and infantile cataract. Functional analysis demonstrated that this variant causes hyperactivity and compensatory downregulation of GLS expression combined with upregulation of the counteracting enzyme GS, supporting pathogenicity. Ser482Cys-GLS likely improves the electrostatic environment of the GLS catalytic site, thereby intrinsically inducing hyperactivity. Alignment of +/−12.000 GLS protein sequences from >1000 genera revealed extreme conservation of Ser482 to the same degree as catalytic residues. Together with the hyperactivity, this indicates that Ser482 is evolutionarily preserved to achieve optimal-but submaximal-GLS activity. In line with GLS hyperactivity, increased glutamate and decreased glutamine concentrations were measured in urine and fibroblasts. In the brain (both grey and white matter), glutamate was also extremely high and glutamine was almost undetectable, demonstrated with magnetic resonance spectroscopic imaging at clinical field strength and subsequently supported at ultra-high field strength. Considering the neurotoxicity of glutamate when present in excess, the strikingly high glutamate concentrations measured in the brain provide an explanation for the developmental delay. Cataract, a known consequence of oxidative stress, was evoked in zebrafish expressing the hypermorphic Ser482Cys-GLS and could be alleviated by inhibition of GLS. The capacity to detoxify reactive oxygen species was reduced upon Ser482Cys-GLS expression, providing an explanation for cataract formation. In conclusion, we describe an inborn error of glutamate metabolism caused by a GLS hyperactivity variant, illustrating the importance of balanced GLS activity.
Introduction
The amino acid glutamate is best known for its role as excitatory neurotransmitter, but also serves as a substrate for other key metabolites including the anti-oxidant glutathione (1) (2) (3) . Glutamate homeostasis is mainly warranted by two enzymes: glutamine synthetase (GS; EC 6.3.1.2) and glutaminase (GLS; EC 3.5.1.2). GS converts glutamate into glutamine and is ubiquitously expressed (4) . GLS catalyzes the deamination of glutamine into glutamate and ammonia and exists in the following two isoforms: GLS, which is present in two splice variants kidneytype glutaminase (KGA) and GAC, which is mainly expressed in kidney and brain; and GLS2, which is ubiquitously expressed with the highest expression in the liver (5, 6) .
Inborn errors of metabolism are usually due to severe loss of function of the involved enzymes, hence recessive inheritance. In line, a disturbed equilibrium of glutamate and glutamine was described in patients with GS deficiency, clinically resulting in glutamine deficiency, neonatal epilepsy and early death (7) . Recently, GLS loss of function has been described to cause lethal epileptic encephalopathy and glutamine excess in two families (8) . The description of patients with spastic ataxia and optic atrophy harboring bi-allelic hypomorphic variants in GLS suggests a phenotypic spectrum-presumably depending on the degree of residual activity-that is yet to be uncovered (9) . Theoretically, glutamate homeostasis can also be disturbed by hyperactivity of either enzyme. This option is commonly disregarded as there are only few examples of genetic variants that induce enzyme hyperactivity, glutamate dehydrogenase (GDH) and IDH2 gain of functions (10, 11) . These examples indicate that a heterozygous variant is sufficient to induce overall enzyme hyperactivity.
In this study, we characterize a de novo hypermorphic heterozygous GLS variant found in a patient with infantile onset cataract, skin abnormalities, profound developmental delay and intracerebral glutamate excess. This new inborn error of metabolism illustrates the importance of regulated GLS activity for lens transparency and brain function.
Results

Clinical description
In a female patient, bilateral cataract was diagnosed at the age of 3 months after the parents noticed decreased eye contact and loss of the red light reflex of the pupils on photos (Fig. 1A and Supplementary Material, S1). The proband is the first child of healthy non-consanguineous parents of Dutch descent (Fig. S1A) as indicated by family history and single nucleotide polymorphism (SNP)-array. Gestation and delivery were uneventful. After lens extraction and replacement, eye contact unexpectedly remained absent. By the age of 8 months, delayed development was noted, along with a relative decrease of the head circumference from 0 standard deviations (SD) to −2 SD. She developed recurrent dermatological abnormalities on her extremities, cheeks and ears without pruritus, characterized as erythematic subcutaneous nodules of ∼1 cm (Fig. 1B) . Histopathological analysis of these lesions showed deep perivascular and periglandular lymphohistiocytic infiltrates and pronounced leukocytoclasia at the surface of the dermis and focal vacuolar alterations, hyperkeratosis and parakeratosis of the epidermis. A dermatological diagnosis remained inconclusive. Over time, the girl lost the ability to make meaningful sounds and the ability to sit. She developed profound axial hypotonia leading to kyphoscoliosis. Upon arousal she exhibited uncontrolled motoric agitation and self-injurious behavior. Development remained slow paced. At the most recent follow up at the age of 11 years, she was able to use gestures for communication, to understand verbal single component instructions and to steer her own wheelchair.
Identification of the Ser482Cys-GLS de novo variant
Extensive diagnostic workup unexpectedly revealed extremely low glutamine levels and high glutamate levels in both cortex and white matter as detected consistently with quantitative brain proton magnetic resonance spectroscopy (MRS) and magnetic resonance spectroscopic imaging (MRSI) at 1.5Tesla ( Fig. 1C and Supplementary Material, S1B) and recently also shown at 7Tesla (Fig. 1D and Supplementary Material, S1C). Interestingly, cerebrospinal fluid and plasma levels were unaffected (Supplementary Material, Table S1 ). Brain MRI at the age of 16 months showed delayed myelination (Fig. 1E) . Analyses of stored urine samples similarly showed low concentrations of glutamine and high concentrations of glutamate ( Fig. 1F and Supplementary Material, Table S1 ). The diagnosis remained enigmatic until trio-based whole-exome sequencing (WES) revealed a heterozygous de novo GLS missense variant (NC 000002.11:g.191 795182C > G). Analysis of WES data using recessive filters yielded no rare homozygous damaging variants. The analysis for compound heterozygosity (including correctness of segregation in parents) yielded two genes hit by rare and possibly damaging variants, but based on gene function, absent links with human disease and the high prevalence within the healthy population, these variants were considered as unlikely to contribute to the phenotypes of the patient (supplementary results). The conservative mutation in GLS from serine to cysteine at position 482 NP 055720.3:p.(Ser482Cys) was confirmed by Sanger sequencing (Fig. 1G, supplementary results) . GLS mediates the conversion of glutamine into glutamate; therefore, this genetic change could only be explained if the encoded protein would be hyperactive.
Ser482Cys-GLS leads to GLS hyperactivity
The effect of the Ser482Cys-GLS variant on the activity of the GLS enzyme was assessed in fibroblasts from the patient by quantification of intracellular glutamine and glutamate. The GLS variant indeed resulted in an increased intracellular glutamate/glutamine ratio ( Fig. 2A and B and Supplementary Material, S2A). To validate enhanced catalytic activity of the GLS variant, a HEK293 cell model with inducible expression of Ser482Cys-GLS (KGA, the long splice variant) was generated. Induction of Ser482Cys-GLS again strongly increased the glutamate/glutamine ratio while induction of wild-type GLS had no effect ( 
GLS hyperactivity leads to metabolic compensatory mechanisms
Protein expression of both GLS splice variants KGA and GAC in patient fibroblasts was decreased-rather than increasedcompared to controls, ruling out that increased GLS activity was due to increased protein availability. Conversely, the observed downregulation of GLS protein expression suggests it served as a compensatory mechanism aiming at normalizing glutamine and glutamate concentrations (Fig. 2B ). In support, introduction of Ser482Cys-GLS in HEK293 cells also evoked decreased GAC expression levels (Fig. 2D and Supplementary Material, S2C ). Furthermore, CB-839-induced GLS inhibition restored GLS expression. GLS expression could also be restored by normalization of glutamate levels through depletion of extracellular glutamine, pointing to glutamate as a regulator of GLS expression (Fig. 2D) . Finally, the observation that protein levels of the reciprocal enzyme GS increased upon expression of Ser482Cys-GLS-an effect that could also be reversed through CB-839-mediated GLS inhibition ( Fig. 2B and D) -underlines that cellular efforts were aimed at normalizing glutamine and glutamate concentrations.
Ser482 functions as a highly conserved intrinsic restrictor of GLS activity
Ser482 is located near the catalytic site of GLS, but does not have an identified role in the catalytic process itself (12) . Alignment of +/− 12.000 GLS protein sequences from >1000 genera revealed that Ser482 is a residue with an extremely high degree of evolutionary conservation (conservation score, >0.98) along with residues directly involved in the catalytic process (Fig. 2E) . The Ser482Cys substitution is absent in healthy populations in the databases GoNL (13), gnomAD (14) , ClinVar (15) and ExAC (16) and is expected to be tolerated without overall disturbances of the protein fold. Interestingly, substitution by cysteine-containing a sterically more demanding and less polar thiol group than serine-changes the electrostatic environment of Tyr466, one of the catalytic residues that protonates glutamine and thereby accelerates deamination into glutamate. This change is likely to enhance the propensity for proton donation and thereby to increase the speed of the reaction (Fig. 2F and Supplementary Material, S3).
GLS hyperactivity decreases redox buffer capacity
Oxidative stress is a known consequence of glutamate excess and a common cause of cataract and neuronal injury (17, 18) . In HEK293 cells expressing Ser482Cys-GLS, clearance of a sub-lethal pulse of hydrogen peroxide was impaired with normal basal reactive oxygen species (ROSs) levels (Fig. 3) . This indicates that Ser482Cys-GLS results in a lower capacity for ROS scavenging.
Ser482Cys-GLS induces lens opacification
To explore the causal relationship between Ser482Cys-GLS expression and cataract, we examined the effect of this variant in developing zebrafish embryos. Lens transparency at 5 days post fertilization (dpf) in zebrafish embryos injected with Ser482Cys-GLS cDNA was compared to that in control embryos injected with wild-type GLS or uninjected embryos (Supplementary Material, Fig. S4A ). Of the embryos expressing the Ser482Cys-GLS variant, 34 (72%) of 47 developed structural opacities in the lens, which were not observed in any of the control embryos (Fig. 4A-C and Supplementary Material, S4B-D). GLS inhibition with CB-839 from 6 h post fertilization (hpf) resulted in profoundly decreased formation of structural opacities in the lens of the Ser482Cys-GLS zebrafish embryos ( Fig. 4D and Supplementary Material, Fig. S4E ).
Discussion
We characterize a de novo heterozygous, hyperactive GLS variant found in a patient with infantile onset cataract, skin abnormalities, profound developmental delay and intracerebral glutamate excess. The increased conversion of glutamine into glutamate observed upon introduction of this variant provides a compelling explanation for the strikingly elevated glutamate levels in cerebro and-in view of the central role of glutamate in brain functioning-likely explains the developmental delay. Furthermore, zebrafish studies unexpectedly reveal that introducing the hypermorphic GLS variant induces lens opacities. Together with the observations that the lens opacities are amenable to GLS inhibition, this supports a role for GLS activity in cataract formation.
Inborn errors of metabolism are usually due to bi-allelic or mono-allelic loss-of-function variants with few exceptions. Of these, hyperinsulinism-hyperammonemia syndrome is caused by increased sensitivity of the enzyme GDH to allosteric activation and D-2-hydroxyglutaric aciduria is caused by a neomorphic function of the enzyme IDH2 (19, 20) . The variant described here truly increases enzymatic activity (Supplemental discussion) likely due to an improved electrostatic environment of the GLS catalytic site. To the best of our knowledge, this nature of hypermorphic gain of function in which activity is intrinsically increased by improvement of the catalytic machinery has not been described before. Although rare by nature, it is possible that the current paradigm-heterozygous variants in enzyme encoding genes are usually harmless-hampers identification of comparable disease causing hypermorphic variants in enzyme encoding genes.
The cellular efforts, aimed at counteracting the effects of the hyperactive enzyme by decreasing GLS protein availability while increasing the reciprocal enzyme GS, underline that increased GLS activity is detrimental. Our data underline the observation by Krebs in 1935 that glutamate acts as a sensor for GLS regulation and reveal that glutamate not only affects GLS enzyme kinetics but also its expression. The extremely high degree of conservation of the hypermorphic residue across >1000 genera-comparable only to residues directly involved in the enzymatic conversion of glutamine into glutamate-suggests that the serine residue serves as a built-in restrictor, ensuring submaximal activity rather than maximal enzyme activity of GLS.
A point of interest is the observation that the ratio between glutamate and glutamine was increased in brain and urine, while it remained unaltered in CSF and plasma. We postulate that this discrepancy is explained by the degree to which glutamine and glutamate levels are controlled by GLS. Tissues with abundant expression of GLS-neurons and kidney-are mainly under GLS control (6) . The relative importance of GLS within the brain is illustrated by a high glutamate/glutamine ratio (2:1) in normal population (21) . GLS overactivity may be masked in other tissues in which GLS is only one of several players-including GS-that together regulate glutamine and glutamate levels. The reduced importance of GLS in plasma is reflected by the significantly lower ratio of glutamate/glutamine (1:15) (22) . Further supporting this hypothesis, the ratio is even lower (∼1:100) in CSF, which is produced by choroid plexus from plasma by glial cells that are known to have high GS expression (4) (22) . The striking contrast between CSF and brain could be regarded as a cautionary note: CSF should not be readily regarded as a proxy for the brain.
Under physiological conditions, glutamate is important for redox homeostasis as it is the precursor of the anti-oxidant glutathione (2) . Glutamate excess, however, is associated with oxidative stress, a common cause of cataract and neuronal damage (17, 18) . We show that GLS hyperactivity indeed leads to decreased capacity for redox buffering, which can result in oxidative stress. We therefore postulate that glutamate excess contributes to the ophthalmologic phenotype of our patient. In the aqueous humor-nourishing the lens-glutamate concentrations are strictly regulated and even kept low by metabolism and transport (23) . Exposure to glutamate causes cataract in chick and rat embryos (17, 24, 25) . In line with the phenotype of the affected patient, zebrafish expressing Ser482Cys-GLS develop lens opacities, which could be largely prevented by GLS inhibition. Interestingly, neurons and lens cells are both of ectodermal origin, as is the skin, and share similarities in expression and regulation of glutamate receptors, supporting the notion that disturbed glutamate homeostasis not only affects the brain, but also skin and lens (26) . Glutamate excitotoxicity has been associated with epilepsy, numerous neurodegenerative diseases, self-injury and agitated behavior (18, 27) . The measured glutamate excess in the brain of our patient might therefore provide a plausible explanation for the self-injury behavior and developmental delay of our patient.
Interestingly, other defects affecting glutamate homeostasis lead to neurological phenotypes as well. Under physiological circumstances, homeostasis of glutamine and glutamate in the brain is strictly regulated by neuronal GLS and astrocytic GS via the glutamine-glutamate shuttle (4) . GLS loss-of-function variants lead to a phenotypic spectrum. The first description was of a late-childhood onset disease, including optic atrophy and spastic ataxia (9) . Recently, bi-allelic loss-of-function variants in GLS were described to cause lethal, neonatal onset encephalopathy characterized by respiratory failure, status epilepticus and early death within weeks after birth (8) . These patients had simplified gyral patterns and showed destructions of initially normal-appearing brain structures. Both the reported hiccups during pregnancy and the simplified gyral patterns on imaging suggest the damage has its onset prenatally. Given the truncating mutations present in the latter phenotype, it is tempting to speculate a dose effect relationship explaining the phenotypic spectrum. This inborn error-together with GLS hyperactivityillustrates the importance of proper GLS activity for both brain physiology and morphology.
Deficiency of GS-performing the reversed reaction of GLSresults in decreased glutamine levels but normal glutamate levels and hyperammonemia. This has been reported in three individuals who exhibited neonatal encephalopathy, seizures and respiratory failure and early death (28) . The absence of epilepsy in our patient with GLS hyperactivity despite increased glutamate levels on brain MRSI is unexpected as glutamate excitotoxicity is considered a critical factor in the initiation of epileptic seizures (29) . Seizures can be provoked by either increased glutamate release into the synaptic cleft or decreased re-uptake or recycling from the synaptic cleft, which implies that glutamate levels in the synaptic cleft of our patient are unaffected despite overall brain glutamate abundance. The phenotypic neurological spectrum of these patients shows the importance of strictly regulated glutamate homeostasis for neurological functioning.
A limitation of our study is that only a single patient with a hyperactive variant in GLS could be identified. Hyperactive variants are extremely uncommon, especially in a well-conserved catalytic area like in GLS. Intolerance to loss of function in GLS is likely high, meaning that mutations will likely be lethal. These factors contribute to a limited patient pool. While definite pathogenic conclusions are considered difficult based on evidence from unique subjects, when adequately studied, these cases can be regarded as experiments of nature and provide invaluable insights. Such is the case here, were we provide strong evidence that GLS hyperactivity causes a new metabolic disorder of glutamate metabolism. Our study furthermore provides insight into the regulation of GLS activity and illustrates the importance of appropriate GLS activity for human brain function, skin and lens transparency.
Materials and Methods
Clinical phenotyping, diagnostics and exome sequencing
Clinical phenotyping was performed and diagnostic tests were requested by metabolic pediatricians, clinical geneticists, ophthalmologist, neurologists and dermatologist. Amino acids analyses in urine were performed on a Biochrom30 analyzer. In the brain, these were determined with quantitative MRS and MRSI at 1.5Tesla at the age of 2 and 3 years and with MRSI at 7Tesla at the age of 14 years. Genetic analysis was performed by triobased whole-exome sequencing and Sanger sequencing. See supplementary methods for details.
GLS activity
GLS activity was determined in patient fibroblasts and in human embryonic kidney 293 (HEK293) cells stably transfected with either wild-type or Ser482Cys-GLS (KGA isoform) or an empty vector (EV), in absence or presence of different concentrations of the allosteric GLS inhibitor CB-839 (30) . GLS activity was defined as the formation of glutamate from glutamine, quantified by ultra-performance liquid chromatography tandem mass spectrometry (31) . Protein expression was assessed by Western Blot.
Conservation analysis
Sequences homologous to human GLS from the non-redundant protein collection at National Center for Biotechnology Information were aligned in SeaView (32) . Obvious partial sequences as well as all protein data bank (pdb) sequences were removed, which resulted in about 12.000 sequences. The consensus were determined in JalView (33) and fraction of the modal residue in a column were used for generating a color gradients, which was mapped onto the GLS structure as a measure of conservation (consensus score).
Reactive oxygen species
ROS-levels were quantified by flow cytometry (BD FACSCalibur TM )
as previously described in wild-type GLS or Ser482Cys-GLS transfected HEK293 cells (34) .
Animal model
Zebrafish (Danio rerio) embryos were microinjected at the 1-cell stage with DNA constructs coding for wild-type or Ser482Cys-GLS (KGA isoform). Uninjected zebrafish embryos were used as controls. The embryos were kept under standard laboratory conditions, either in the absence or in the presence of the GLS inhibitor CB-839, prior to assessment of glutamine and glutamate concentrations and lens opacity at 5 dpf.
Statistics
Statistical analyses were performed by ANOVA, post-hoc Tukey's test using International Business Machines Statistical Package for the Social Sciences (IBM SPSS) statistics 21.
Study approval
The proband's parents provided written informed consent for all aspects of the study. Zebrafish experiments were carried out in accordance with the guidelines of the Animal Experimentation Committee of the Royal Netherlands Academy of Arts and Sciences. For more detailed information, see supplementary materials and methods.
Supplementary Material
Supplementary Material is available at HMG online.
